{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T17:49:27Z","timestamp":1795024167563,"version":"4.10.2"},"reference-count":123,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T00:00:00Z","timestamp":1628208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T00:00:00Z","timestamp":1628208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1038\/s41581-021-00462-y","type":"journal-article","created":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T07:02:51Z","timestamp":1628233371000},"page":"740-750","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":334,"title":["Trajectories of kidney function in diabetes: a clinicopathological update"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4108-5229","authenticated-orcid":false,"given":"Megumi","family":"Oshima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7737-935X","authenticated-orcid":false,"given":"Miho","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3264-9691","authenticated-orcid":false,"given":"Masayuki","family":"Yamanouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Toyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Furuichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0123-3645","authenticated-orcid":false,"given":"Takashi","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,6]]},"reference":[{"key":"462_CR1","unstructured":"United States Renal Data System. 2019 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States (National Institute of Diabetes and Digestive and Kidney Diseases, 2019)."},{"key":"462_CR2","unstructured":"International Diabetes Federation. IDF Diabetes Atlas 8th Edn (IDF, 2017)."},{"issue":"Suppl. 4","key":"462_CR3","first-page":"S1","volume":"98","author":"Kidney Disease: Improving Global Outcomes Diabetes Work Group","year":"2020","unstructured":"Kidney Disease: Improving Global Outcomes Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 98(Suppl. 4), S1\u2013S115 (2020).","journal-title":"Kidney Int."},{"key":"462_CR4","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1053\/j.ajkd.2012.07.005","volume":"60","author":"National Kidney Foundation","year":"2012","unstructured":"National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am. J. Kidney Dis. 60, 850\u2013886 (2012).","journal-title":"Am. J. Kidney Dis."},{"key":"462_CR5","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1001\/jama.2016.10924","volume":"316","author":"M Afkarian","year":"2016","unstructured":"Afkarian, M. et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA 316, 602\u2013610 (2016).","journal-title":"JAMA"},{"key":"462_CR6","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1093\/ndt\/gfw417","volume":"33","author":"K Furuichi","year":"2018","unstructured":"Furuichi, K. et al. Nationwide multicentre kidney biopsy study of Japanese patients with type 2 diabetes. Nephrol. Dial. Transpl. 33, 138\u2013148 (2018).","journal-title":"Nephrol. Dial. Transpl."},{"key":"462_CR7","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.kint.2016.01.023","volume":"90","author":"CQ Klessens","year":"2016","unstructured":"Klessens, C. Q. et al. An autopsy study suggests that diabetic nephropathy is underdiagnosed. Kidney Int. 90, 149\u2013156 (2016).","journal-title":"Kidney Int."},{"key":"462_CR8","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.kint.2016.02.042","volume":"90","author":"SM Said","year":"2016","unstructured":"Said, S. M. & Nasr, S. H. Silent diabetic nephropathy. Kidney Int. 90, 24\u201326 (2016).","journal-title":"Kidney Int."},{"issue":"Suppl. 2","key":"462_CR9","doi-asserted-by":"publisher","first-page":"64","DOI":"10.2337\/diab.32.2.S64","volume":"32","author":"CE Mogensen","year":"1983","unstructured":"Mogensen, C. E., Christensen, C. K. & Vittinghus, E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes 32(Suppl. 2), 64\u201378 (1983).","journal-title":"Diabetes"},{"key":"462_CR10","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1681\/ASN.2016060666","volume":"28","author":"L Tonneijck","year":"2017","unstructured":"Tonneijck, L. et al. Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment. J. Am. Soc. Nephrol. 28, 1023\u20131039 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"462_CR11","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S2213-8587(18)30313-9","volume":"7","author":"J Coresh","year":"2019","unstructured":"Coresh, J. et al. Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. Lancet Diabetes Endocrinol. 7, 115\u2013127 (2019).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"462_CR12","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.2337\/diabetes.54.10.2983","volume":"54","author":"S Araki","year":"2005","unstructured":"Araki, S. et al. Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes. Diabetes 54, 2983\u20132987 (2005).","journal-title":"Diabetes"},{"key":"462_CR13","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1093\/ndt\/gfh470","volume":"19","author":"P Gaede","year":"2004","unstructured":"Gaede, P., Tarnow, L., Vedel, P., Parving, H. H. & Pedersen, O. Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. Nephrol. Dial. Transpl. 19, 2784\u20132788 (2004).","journal-title":"Nephrol. Dial. Transpl."},{"key":"462_CR14","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.2337\/diacare.24.11.1972","volume":"24","author":"P Hovind","year":"2001","unstructured":"Hovind, P. et al. Remission of nephrotic-range albuminuria in type 1 diabetic patients. Diabetes Care 24, 1972\u20131977 (2001).","journal-title":"Diabetes Care"},{"key":"462_CR15","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1007\/s00125-005-1937-6","volume":"48","author":"K Rossing","year":"2005","unstructured":"Rossing, K., Christensen, P. K., Hovind, P. & Parving, H. H. Remission of nephrotic-range albuminuria reduces risk of end-stage renal disease and improves survival in type 2 diabetic patients. Diabetologia 48, 2241\u20132247 (2005).","journal-title":"Diabetologia"},{"key":"462_CR16","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1681\/ASN.2020050723","volume":"31","author":"M Oshima","year":"2020","unstructured":"Oshima, M. et al. Early change in albuminuria with canagliflozin predicts kidney and cardiovascular outcomes: a post hoc analysis from the CREDENCE Trial. J. Am. Soc. Nephrol. 31, 2925\u20132936 (2020).","journal-title":"J. Am. Soc. Nephrol."},{"key":"462_CR17","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1681\/ASN.2006080872","volume":"18","author":"BA Perkins","year":"2007","unstructured":"Perkins, B. A. et al. Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. J. Am. Soc. Nephrol. 18, 1353\u20131361 (2007).","journal-title":"J. Am. Soc. Nephrol."},{"key":"462_CR18","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.2337\/dc13-0281","volume":"36","author":"H Yokoyama","year":"2013","unstructured":"Yokoyama, H. et al. Association between remission of macroalbuminuria and preservation of renal function in patients with type 2 diabetes with overt proteinuria. Diabetes Care 36, 3227\u20133233 (2013).","journal-title":"Diabetes Care"},{"key":"462_CR19","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.2215\/CJN.02870316","volume":"11","author":"IH de Boer","year":"2016","unstructured":"de Boer, I. H. et al. Albuminuria changes and cardiovascular and renal outcomes in type 1 diabetes: The DCCT\/EDIC Study. Clin. J. Am. Soc. Nephrol. 11, 1969\u20131977 (2016).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"462_CR20","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1056\/NEJMoa011489","volume":"345","author":"HH Parving","year":"2001","unstructured":"Parving, H. H. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 345, 870\u2013878 (2001).","journal-title":"N. Engl. J. Med."},{"key":"462_CR21","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner, B. M. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861\u2013869 (2001).","journal-title":"N. Engl. J. Med."},{"key":"462_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0129036","volume":"10","author":"M Baba","year":"2015","unstructured":"Baba, M. et al. Longitudinal study of the decline in renal function in healthy subjects. PLoS One 10, e0129036 (2015).","journal-title":"PLoS One"},{"key":"462_CR23","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.2337\/dc18-0277","volume":"41","author":"B Warren","year":"2018","unstructured":"Warren, B. et al. Diabetes and trajectories of estimated glomerular filtration rate: a prospective cohort analysis of the atherosclerosis risk in communities study. Diabetes Care 41, 1646\u20131653 (2018).","journal-title":"Diabetes Care"},{"key":"462_CR24","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/j.kint.2016.10.046","volume":"91","author":"AS Krolewski","year":"2017","unstructured":"Krolewski, A. S., Skupien, J., Rossing, P. & Warram, J. H. Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes. Kidney Int. 91, 1300\u20131311 (2017).","journal-title":"Kidney Int."},{"key":"462_CR25","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/kisup.2012.65","volume":"3","author":"No Authors Listed","year":"2013","unstructured":"No Authors Listed. Chapter 2: Definition, identification, and prediction of CKD progression. Kidney Int. Suppl. 3, 63\u201372 (2013).","journal-title":"Kidney Int. Suppl."},{"key":"462_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2019-000902","volume":"8","author":"Y Yoshida","year":"2020","unstructured":"Yoshida, Y. et al. Conditions, pathogenesis, and progression of diabetic kidney disease and early decliner in Japan. BMJ Open Diabetes Res. Care 8, e000902 (2020).","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"462_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2019-001157","volume":"8","author":"K Furuichi","year":"2020","unstructured":"Furuichi, K. et al. Clinicopathological features of fast eGFR decliners among patients with diabetic nephropathy. BMJ Open Diabetes Res. Care 8, e001157 (2020).","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"462_CR28","doi-asserted-by":"publisher","first-page":"226","DOI":"10.2337\/dc13-0985","volume":"37","author":"AS Krolewski","year":"2014","unstructured":"Krolewski, A. S. et al. Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria. Diabetes Care 37, 226\u2013234 (2014).","journal-title":"Diabetes Care"},{"key":"462_CR29","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink, H. J. L. et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 383, 1436\u20131446 (2020).","journal-title":"N. Engl. J. Med."},{"key":"462_CR30","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1681\/ASN.2015060687","volume":"27","author":"CP Kovesdy","year":"2016","unstructured":"Kovesdy, C. P. et al. Past decline versus current eGFR and subsequent ESRD Risk. J. Am. Soc. Nephrol. 27, 2447\u20132455 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"462_CR31","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.ijcard.2015.09.090","volume":"202","author":"TC Turin","year":"2016","unstructured":"Turin, T. C. et al. Magnitude of rate of change in kidney function and future risk of cardiovascular events. Int. J. Cardiol. 202, 657\u2013665 (2016).","journal-title":"Int. J. Cardiol."},{"key":"462_CR32","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1007\/s00125-019-4948-4","volume":"62","author":"M Oshima","year":"2019","unstructured":"Oshima, M. et al. The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study. Diabetologia 62, 1988\u20131997 (2019).","journal-title":"Diabetologia"},{"key":"462_CR33","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S2213-8587(15)00094-7","volume":"3","author":"E Porrini","year":"2015","unstructured":"Porrini, E. et al. Non-proteinuric pathways in loss of renal function in patients with type 2 diabetes. Lancet Diabetes Endocrinol. 3, 382\u2013391 (2015).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"462_CR34","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1001\/jama.289.24.3273","volume":"289","author":"HJ Kramer","year":"2003","unstructured":"Kramer, H. J., Nguyen, Q. D., Curhan, G. & Hsu, C. Y. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 289, 3273\u20133277 (2003).","journal-title":"JAMA"},{"key":"462_CR35","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2337\/diacare.27.1.195","volume":"27","author":"RJ MacIsaac","year":"2004","unstructured":"MacIsaac, R. J. et al. Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care 27, 195\u2013200 (2004).","journal-title":"Diabetes Care"},{"key":"462_CR36","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1093\/ndt\/gfn603","volume":"24","author":"H Yokoyama","year":"2009","unstructured":"Yokoyama, H. et al. Prevalence of albuminuria and renal insufficiency and associated clinical factors in type 2 diabetes: the Japan Diabetes Clinical Data Management study (JDDM15). Nephrol. Dial. Transpl. 24, 1212\u20131219 (2009).","journal-title":"Nephrol. Dial. Transpl."},{"key":"462_CR37","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.2337\/dc08-2186","volume":"32","author":"MC Thomas","year":"2009","unstructured":"Thomas, M. C. et al. Nonalbuminuric renal impairment in type 2 diabetic patients and in the general population (national evaluation of the frequency of renal impairment cO-existing with NIDDM [NEFRON] 11). Diabetes Care 32, 1497\u20131502 (2009).","journal-title":"Diabetes Care"},{"key":"462_CR38","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1001\/archinte.168.22.2440","volume":"168","author":"LD Bash","year":"2008","unstructured":"Bash, L. D., Selvin, E., Steffes, M., Coresh, J. & Astor, B. C. Poor glycemic control in diabetes and the risk of incident chronic kidney disease even in the absence of albuminuria and retinopathy: Atherosclerosis Risk in Communities (ARIC) Study. Arch. Intern. Med. 168, 2440\u20132447 (2008).","journal-title":"Arch. Intern. Med."},{"key":"462_CR39","doi-asserted-by":"publisher","first-page":"891","DOI":"10.2337\/dc18-1320","volume":"42","author":"M Yamanouchi","year":"2019","unstructured":"Yamanouchi, M. et al. Nonproteinuric versus proteinuric phenotypes in diabetic kidney disease: a propensity score-matched analysis of a nationwide, biopsy-based cohort study. Diabetes Care 42, 891\u2013902 (2019).","journal-title":"Diabetes Care"},{"key":"462_CR40","doi-asserted-by":"publisher","first-page":"122","DOI":"10.2337\/dc19-1438","volume":"43","author":"O Buyadaa","year":"2020","unstructured":"Buyadaa, O., Magliano, D. J., Salim, A., Koye, D. N. & Shaw, J. E. Risk of rapid kidney function decline, all-cause mortality, and major cardiovascular events in nonalbuminuric chronic kidney disease in type 2 diabetes. Diabetes Care 43, 122\u2013129 (2020).","journal-title":"Diabetes Care"},{"key":"462_CR41","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.2337\/dc19-0349","volume":"42","author":"D Vistisen","year":"2019","unstructured":"Vistisen, D. et al. Progressive decline in estimated glomerular filtration rate in patients with diabetes after moderate loss in kidney function-even without albuminuria. Diabetes Care 42, 1886\u20131894 (2019).","journal-title":"Diabetes Care"},{"key":"462_CR42","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.2337\/dc19-2049","volume":"43","author":"H Yokoyama","year":"2020","unstructured":"Yokoyama, H. et al. The prognosis of patients with type 2 diabetes and nonalbuminuric diabetic kidney disease is not always poor: implication of the effects of coexisting macrovascular complications (JDDM 54). Diabetes Care 43, 1102\u20131110 (2020).","journal-title":"Diabetes Care"},{"key":"462_CR43","doi-asserted-by":"publisher","first-page":"901","DOI":"10.2337\/dc20-2586","volume":"44","author":"D Vistisen","year":"2021","unstructured":"Vistisen, D. et al. A validated prediction model for end-stage kidney disease in type 1 diabetes. Diabetes Care 44, 901\u2013907 (2021).","journal-title":"Diabetes Care"},{"key":"462_CR44","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1161\/CIRCULATIONAHA.115.018844","volume":"133","author":"D Vistisen","year":"2016","unstructured":"Vistisen, D. et al. Prediction of first cardiovascular disease event in type 1 diabetes mellitus: the steno type 1 risk engine. Circulation 133, 1058\u20131066 (2016).","journal-title":"Circulation"},{"key":"462_CR45","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s10157-013-0879-4","volume":"18","author":"T Wada","year":"2014","unstructured":"Wada, T. et al. Clinical impact of albuminuria and glomerular filtration rate on renal and cardiovascular events, and all-cause mortality in Japanese patients with type 2 diabetes. Clin. Exp. Nephrol. 18, 613\u2013620 (2014).","journal-title":"Clin. Exp. Nephrol."},{"key":"462_CR46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0071810","volume":"8","author":"T Toyama","year":"2013","unstructured":"Toyama, T. et al. The impacts of albuminuria and low eGFR on the risk of cardiovascular death, all-cause mortality, and renal events in diabetic patients: meta-analysis. PLoS One 8, e71810 (2013).","journal-title":"PLoS One"},{"key":"462_CR47","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1053\/j.ajkd.2017.08.010","volume":"71","author":"M Weldegiorgis","year":"2018","unstructured":"Weldegiorgis, M. et al. Longitudinal estimated GFR trajectories in patients with and without type 2 diabetes and nephropathy. Am. J. Kidney Dis. 71, 91\u2013101 (2018).","journal-title":"Am. J. Kidney Dis."},{"key":"462_CR48","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1007\/s00125-019-05052-z","volume":"63","author":"M Colombo","year":"2020","unstructured":"Colombo, M. et al. Predicting renal disease progression in a large contemporary cohort with type 1 diabetes mellitus. Diabetologia 63, 636\u2013647 (2020).","journal-title":"Diabetologia"},{"key":"462_CR49","doi-asserted-by":"publisher","first-page":"107875","DOI":"10.1016\/j.jdiacomp.2021.107875","volume":"35","author":"SI Stoilov","year":"2021","unstructured":"Stoilov, S. I., Fountoulakis, N., Panagiotou, A., Thomas, S. & Karalliedde, J. Non-linear renal function decline is frequent in patients with type 2 diabetes who progress fast to end-stage renal disease and is associated with African-Caribbean ethnicity and HbA1c variability. J. Diabetes Complicat. 35, 107875 (2021).","journal-title":"J. Diabetes Complicat."},{"key":"462_CR50","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12882-021-02282-5","volume":"22","author":"I Ali","year":"2021","unstructured":"Ali, I., Chinnadurai, R., Ibrahim, S. T. & Kalra, P. A. Adverse outcomes associated with rapid linear and non-linear patterns of chronic kidney disease progression. BMC Nephrol. 22, 82 (2021).","journal-title":"BMC Nephrol."},{"key":"462_CR51","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1681\/ASN.2010010010","volume":"21","author":"TW Tervaert","year":"2010","unstructured":"Tervaert, T. W. et al. Pathologic classification of diabetic nephropathy. J. Am. Soc. Nephrol. 21, 556\u2013563 (2010).","journal-title":"J. Am. Soc. Nephrol."},{"key":"462_CR52","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1007\/s10157-017-1485-7","volume":"22","author":"K Furuichi","year":"2018","unstructured":"Furuichi, K. et al. Clinicopathological analysis of biopsy-proven diabetic nephropathy based on the Japanese classification of diabetic nephropathy. Clin. Exp. Nephrol. 22, 570\u2013582 (2018).","journal-title":"Clin. Exp. Nephrol."},{"key":"462_CR53","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.humpath.2018.01.019","volume":"75","author":"F Yasuda","year":"2018","unstructured":"Yasuda, F. et al. Importance of frequency and morphological characteristics of nodular diabetic glomerulosclerosis in diabetic nephropathy. Hum. Pathol. 75, 95\u2013103 (2018).","journal-title":"Hum. Pathol."},{"key":"462_CR54","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1093\/ndt\/gfu279","volume":"30","author":"M Mauer","year":"2015","unstructured":"Mauer, M., Caramori, M. L., Fioretto, P. & Najafian, B. Glomerular structural-functional relationship models of diabetic nephropathy are robust in type 1 diabetic patients. Nephrol. Dial. Transpl. 30, 918\u2013923 (2015).","journal-title":"Nephrol. Dial. Transpl."},{"key":"462_CR55","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.2337\/db07-0019","volume":"56","author":"M Toyoda","year":"2007","unstructured":"Toyoda, M., Najafian, B., Kim, Y., Caramori, M. L. & Mauer, M. Podocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathy. Diabetes 56, 2155\u20132160 (2007).","journal-title":"Diabetes"},{"key":"462_CR56","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1097\/01.ASN.0000057854.32413.81","volume":"14","author":"B Najafian","year":"2003","unstructured":"Najafian, B., Kim, Y., Crosson, J. T. & Mauer, M. Atubular glomeruli and glomerulotubular junction abnormalities in diabetic nephropathy. J. Am. Soc. Nephrol. 14, 908\u2013917 (2003).","journal-title":"J. Am. Soc. Nephrol."},{"key":"462_CR57","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1007\/s00125-008-1051-7","volume":"51","author":"P Fioretto","year":"2008","unstructured":"Fioretto, P., Caramori, M. L. & Mauer, M. The kidney in diabetes: dynamic pathways of injury and repair. The Camillo Golgi Lecture 2007. Diabetologia 51, 1347\u20131355 (2008).","journal-title":"Diabetologia"},{"key":"462_CR58","doi-asserted-by":"publisher","first-page":"254","DOI":"10.2215\/CJN.05760515","volume":"11","author":"GD Fufaa","year":"2016","unstructured":"Fufaa, G. D. et al. Structural predictors of loss of renal function in American Indians with type 2 diabetes. Clin. J. Am. Soc. Nephrol. 11, 254\u2013261 (2016).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"462_CR59","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.jdiacomp.2019.02.002","volume":"33","author":"T Moriya","year":"2019","unstructured":"Moriya, T., Yamagishi, T., Matsubara, M. & Ouchi, M. Serial renal biopsies in normo- and microalbuminuric patients with type 2 diabetes demonstrate that loss of renal function is associated with a reduction in glomerular filtration surface secondary to mesangial expansion. J. Diabetes Complicat. 33, 368\u2013373 (2019).","journal-title":"J. Diabetes Complicat."},{"key":"462_CR60","doi-asserted-by":"publisher","first-page":"3655","DOI":"10.2337\/dc13-0298","volume":"36","author":"M Shimizu","year":"2013","unstructured":"Shimizu, M. et al. Long-term outcomes of Japanese type 2 diabetic patients with biopsy-proven diabetic nephropathy. Diabetes Care 36, 3655\u20133662 (2013).","journal-title":"Diabetes Care"},{"key":"462_CR61","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1007\/s10157-018-1556-4","volume":"22","author":"K Furuichi","year":"2018","unstructured":"Furuichi, K., Shimizu, M., Okada, H., Narita, I. & Wada, T. Clinico-pathological features of kidney disease in diabetic cases. Clin. Exp. Nephrol. 22, 1046\u20131051 (2018).","journal-title":"Clin. Exp. Nephrol."},{"key":"462_CR62","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1681\/ASN.2018111166","volume":"30","author":"HC Looker","year":"2019","unstructured":"Looker, H. C. et al. Changes in albuminuria but Not GFR are associated with early changes in kidney structure in type 2 diabetes. J. Am. Soc. Nephrol. 30, 1049\u20131059 (2019).","journal-title":"J. Am. Soc. Nephrol."},{"key":"462_CR63","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1056\/NEJM199807093390202","volume":"339","author":"P Fioretto","year":"1998","unstructured":"Fioretto, P., Steffes, M. W., Sutherland, D. E., Goetz, F. C. & Mauer, M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N. Engl. J. Med. 339, 69\u201375 (1998).","journal-title":"N. Engl. J. Med."},{"key":"462_CR64","doi-asserted-by":"publisher","first-page":"107847","DOI":"10.1016\/j.jdiacomp.2021.107847","volume":"35","author":"T Moriya","year":"2021","unstructured":"Moriya, T., Yamagishi, T., Yoshida, Y., Matsubara, M. & Ouchi, M. Arteriolar hyalinosis is related to rapid GFR decline and long-standing GFR changes observed on renal biopsies in normo-microalbuminuric type 2 diabetic patients. J. Diabetes Complicat. 35, 107847 (2021).","journal-title":"J. Diabetes Complicat."},{"key":"462_CR65","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1002\/dmrr.2633","volume":"31","author":"K Mise","year":"2015","unstructured":"Mise, K. et al. Clinical and pathological predictors of estimated GFR decline in patients with type 2 diabetes and overt proteinuric diabetic nephropathy. Diabetes Metab. Res. Rev. 31, 572\u2013581 (2015).","journal-title":"Diabetes Metab. Res. Rev."},{"key":"462_CR66","doi-asserted-by":"publisher","first-page":"3620","DOI":"10.2337\/dc12-2572","volume":"36","author":"EI Ekinci","year":"2013","unstructured":"Ekinci, E. I. et al. Renal structure in normoalbuminuric and albuminuric patients with type 2 diabetes and impaired renal function. Diabetes Care 36, 3620\u20133626 (2013).","journal-title":"Diabetes Care"},{"key":"462_CR67","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s10157-020-01881-0","volume":"24","author":"M Yamanouchi","year":"2020","unstructured":"Yamanouchi, M., Furuichi, K., Hoshino, J., Ubara, Y. & Wada, T. Nonproteinuric diabetic kidney disease. Clin. Exp. Nephrol. 24, 573\u2013581 (2020).","journal-title":"Clin. Exp. Nephrol."},{"key":"462_CR68","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s10157-013-0870-0","volume":"18","author":"M Shimizu","year":"2014","unstructured":"Shimizu, M. et al. Kidney lesions in diabetic patients with normoalbuminuric renal insufficiency. Clin. Exp. Nephrol. 18, 305\u2013312 (2014).","journal-title":"Clin. Exp. Nephrol."},{"key":"462_CR69","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.2337\/diabetes.52.4.1036","volume":"52","author":"ML Caramori","year":"2003","unstructured":"Caramori, M. L., Fioretto, P. & Mauer, M. Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: an indicator of more advanced glomerular lesions. Diabetes 52, 1036\u20131040 (2003).","journal-title":"Diabetes"},{"key":"462_CR70","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/ndt\/gfu250","volume":"30","author":"Y An","year":"2015","unstructured":"An, Y. et al. Renal histologic changes and the outcome in patients with diabetic nephropathy. Nephrol. Dial. Transpl. 30, 257\u2013266 (2015).","journal-title":"Nephrol. Dial. Transpl."},{"key":"462_CR71","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.diabres.2017.03.006","volume":"127","author":"K Mise","year":"2017","unstructured":"Mise, K. et al. Nodular lesions in diabetic nephropathy: collagen staining and renal prognosis. Diabetes Res. Clin. Pract. 127, 187\u2013197 (2017).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"462_CR72","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10157-012-0711-6","volume":"17","author":"T Wada","year":"2013","unstructured":"Wada, T. et al. Nodular lesions and mesangiolysis in diabetic nephropathy. Clin. Exp. Nephrol. 17, 3\u20139 (2013).","journal-title":"Clin. Exp. Nephrol."},{"key":"462_CR73","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1097\/TP.0b013e31825e4a5f","volume":"94","author":"I Nyumura","year":"2012","unstructured":"Nyumura, I., Honda, K., Tanabe, K., Teraoka, S. & Iwamoto, Y. Early histologic lesions and risk factors for recurrence of diabetic kidney disease after kidney transplantation. Transplantation 94, 612\u2013619 (2012).","journal-title":"Transplantation"},{"key":"462_CR74","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.humpath.2007.01.019","volume":"38","author":"LC Stout","year":"2007","unstructured":"Stout, L. C. & Whorton, E. B. Pathogenesis of extra efferent vessel development in diabetic glomeruli. Hum. Pathol. 38, 1167\u20131177 (2007).","journal-title":"Hum. Pathol."},{"key":"462_CR75","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0190923","volume":"13","author":"J Hoshino","year":"2018","unstructured":"Hoshino, J. et al. A new pathological scoring system by the Japanese classification to predict renal outcome in diabetic nephropathy. PLoS One 13, e0190923 (2018).","journal-title":"PLoS One"},{"key":"462_CR76","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1111\/jdi.12981","volume":"10","author":"M Shimizu","year":"2019","unstructured":"Shimizu, M. et al. Association of renal arteriosclerosis and hypertension with renal and cardiovascular outcomes in Japanese type 2 diabetes patients with diabetic nephropathy. J. Diabetes Investig. 10, 1041\u20131049 (2019).","journal-title":"J. Diabetes Investig."},{"key":"462_CR77","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.2337\/dc18-0532","volume":"41","author":"A Heinzel","year":"2018","unstructured":"Heinzel, A. et al. Validation of plasma biomarker candidates for the prediction of eGFR decline in patients with type 2 diabetes. Diabetes Care 41, 1947\u20131954 (2018).","journal-title":"Diabetes Care"},{"key":"462_CR78","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/s41591-019-0415-5","volume":"25","author":"MA Niewczas","year":"2019","unstructured":"Niewczas, M. A. et al. A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes. Nat. Med. 25, 805\u2013813 (2019).","journal-title":"Nat. Med."},{"key":"462_CR79","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.2215\/CJN.10321014","volume":"10","author":"D Dunkler","year":"2015","unstructured":"Dunkler, D. et al. Risk prediction for early CKD in type 2 diabetes. Clin. J. Am. Soc. Nephrol. 10, 1371\u20131379 (2015).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"462_CR80","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2215\/CJN.07650711","volume":"7","author":"G Zoppini","year":"2012","unstructured":"Zoppini, G. et al. Predictors of estimated GFR decline in patients with type 2 diabetes and preserved kidney function. Clin. J. Am. Soc. Nephrol. 7, 401\u2013408 (2012).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"462_CR81","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1093\/ndt\/gfq535","volume":"26","author":"H Afghahi","year":"2011","unstructured":"Afghahi, H. et al. Risk factors for the development of albuminuria and renal impairment in type 2 diabetes \u2014 the Swedish National Diabetes Register (NDR). Nephrol. Dial. Transpl. 26, 1236\u20131243 (2011).","journal-title":"Nephrol. Dial. Transpl."},{"key":"462_CR82","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s00592-019-01293-x","volume":"56","author":"D Kar","year":"2019","unstructured":"Kar, D. et al. Association of smoking and cardiometabolic parameters with albuminuria in people with type 2 diabetes mellitus: a systematic review and meta-analysis. Acta Diabetol. 56, 839\u2013850 (2019).","journal-title":"Acta Diabetol."},{"key":"462_CR83","doi-asserted-by":"publisher","first-page":"517","DOI":"10.4239\/wjd.v10.i11.517","volume":"10","author":"AI Korbut","year":"2019","unstructured":"Korbut, A. I., Klimontov, V. V., Vinogradov, I. V. & Romanov, V. V. Risk factors and urinary biomarkers of non-albuminuric and albuminuric chronic kidney disease in patients with type 2 diabetes. World J. Diabetes 10, 517\u2013533 (2019).","journal-title":"World J. Diabetes"},{"key":"462_CR84","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.kint.2017.11.024","volume":"93","author":"N Nowak","year":"2018","unstructured":"Nowak, N. et al. Markers of early progressive renal decline in type 2 diabetes suggest different implications for etiological studies and prognostic tests development. Kidney Int. 93, 1198\u20131206 (2018).","journal-title":"Kidney Int."},{"key":"462_CR85","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1681\/ASN.2011060627","volume":"23","author":"MA Niewczas","year":"2012","unstructured":"Niewczas, M. A. et al. Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. J. Am. Soc. Nephrol. 23, 507\u2013515 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"462_CR86","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1681\/ASN.2011060628","volume":"23","author":"T Gohda","year":"2012","unstructured":"Gohda, T. et al. Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. J. Am. Soc. Nephrol. 23, 516\u2013524 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"462_CR87","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.kint.2017.02.010","volume":"92","author":"M Yamanouchi","year":"2017","unstructured":"Yamanouchi, M. et al. Improved clinical trial enrollment criterion to identify patients with diabetes at risk of end-stage renal disease. Kidney Int. 92, 258\u2013266 (2017).","journal-title":"Kidney Int."},{"key":"462_CR88","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.1681\/ASN.2016101101","volume":"28","author":"SG Coca","year":"2017","unstructured":"Coca, S. G. et al. Plasma biomarkers and kidney function decline in early and established diabetic kidney disease. J. Am. Soc. Nephrol. 28, 2786\u20132793 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"462_CR89","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/ki.2012.383","volume":"83","author":"MG Wong","year":"2013","unstructured":"Wong, M. G. et al. Circulating bone morphogenetic protein-7 and transforming growth factor-beta1 are better predictors of renal end points in patients with type 2 diabetes mellitus. Kidney Int. 83, 278\u2013284 (2013).","journal-title":"Kidney Int."},{"key":"462_CR90","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1038\/ki.2015.199","volume":"88","author":"HC Looker","year":"2015","unstructured":"Looker, H. C. et al. Biomarkers of rapid chronic kidney disease progression in type 2 diabetes. Kidney Int. 88, 888\u2013896 (2015).","journal-title":"Kidney Int."},{"key":"462_CR91","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S2213-8587(20)30300-4","volume":"8","author":"M Oshima","year":"2020","unstructured":"Oshima, M. et al. Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial. Lancet Diabetes Endocrinol. 8, 903\u2013914 (2020).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"462_CR92","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1053\/j.ajkd.2017.09.026","volume":"71","author":"S Fishbane","year":"2018","unstructured":"Fishbane, S. & Spinowitz, B. Update on anemia in ESRD and earlier stages of CKD: core curriculum 2018. Am. J. Kidney Dis. 71, 423\u2013435 (2018).","journal-title":"Am. J. Kidney Dis."},{"key":"462_CR93","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1681\/ASN.2013090945","volume":"25","author":"P Cravedi","year":"2014","unstructured":"Cravedi, P. et al. Immunosuppressive effects of erythropoietin on human alloreactive T cells. J. Am. Soc. Nephrol. 25, 2003\u20132015 (2014).","journal-title":"J. Am. Soc. Nephrol."},{"key":"462_CR94","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/nep.13518","volume":"24","author":"H Yasuda","year":"2019","unstructured":"Yasuda, H. et al. Erythropoietin signal protected human umbilical vein endothelial cells from high glucose-induced injury. Nephrology 24, 767\u2013774 (2019).","journal-title":"Nephrology"},{"key":"462_CR95","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/bjh.12105","volume":"160","author":"A Hara","year":"2013","unstructured":"Hara, A. et al. Autoantibodies to erythropoietin receptor in patients with immune-mediated diseases: relationship to anaemia with erythroid hypoplasia. Br. J. Haematol. 160, 244\u2013250 (2013).","journal-title":"Br. J. Haematol."},{"key":"462_CR96","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.3899\/jrheum.151430","volume":"43","author":"A Hara","year":"2016","unstructured":"Hara, A. et al. Effect of autoantibodies to erythropoietin receptor in systemic lupus erythematosus with biopsy-proven lupus nephritis. J. Rheumatol. 43, 1328\u20131334 (2016).","journal-title":"J. Rheumatol."},{"key":"462_CR97","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ekir.2017.08.017","volume":"3","author":"A Hara","year":"2018","unstructured":"Hara, A. et al. Clinical and pathological significance of autoantibodies to erythropoietin receptor in type 2 diabetic patients with CKD. Kidney Int. Rep. 3, 133\u2013141 (2018).","journal-title":"Kidney Int. Rep."},{"key":"462_CR98","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.ekir.2020.10.039","volume":"6","author":"M Oshima","year":"2020","unstructured":"Oshima, M. et al. Comparison of circulating biomarkers in predicting diabetic kidney disease progression with autoantibodies to erythropoietin receptor. Kidney Int. Rep. 6, 284\u2013295 (2020).","journal-title":"Kidney Int. Rep."},{"key":"462_CR99","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1093\/ndt\/gfx255","volume":"33","author":"P Bjornstad","year":"2018","unstructured":"Bjornstad, P. et al. Plasma biomarkers improve prediction of diabetic kidney disease in adults with type 1 diabetes over a 12-year follow-up: CACTI study. Nephrol. Dial. Transpl. 33, 1189\u20131196 (2018).","journal-title":"Nephrol. Dial. Transpl."},{"key":"462_CR100","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2337\/dc16-2202","volume":"40","author":"G Mayer","year":"2017","unstructured":"Mayer, G. et al. Systems biology-derived biomarkers to predict progression of renal function decline in type 2 diabetes. Diabetes Care 40, 391\u2013397 (2017).","journal-title":"Diabetes Care"},{"key":"462_CR101","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S2213-8587(20)30026-7","volume":"8","author":"N Tofte","year":"2020","unstructured":"Tofte, N. et al. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. Lancet Diabetes Endocrinol. 8, 301\u2013312 (2020).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"462_CR102","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.2337\/dc17-0911","volume":"40","author":"KE Peters","year":"2017","unstructured":"Peters, K. E. et al. Identification of novel circulating biomarkers predicting rapid decline in renal function in type 2 diabetes: the Fremantle diabetes study phase II. Diabetes Care 40, 1548\u20131555 (2017).","journal-title":"Diabetes Care"},{"key":"462_CR103","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1007\/s00125-019-4915-0","volume":"62","author":"M Colombo","year":"2019","unstructured":"Colombo, M. et al. Biomarker panels associated with progression of renal disease in type 1 diabetes. Diabetologia 62, 1616\u20131627 (2019).","journal-title":"Diabetologia"},{"key":"462_CR104","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.3390\/jcm9093006","volume":"9","author":"VV Klimontov","year":"2020","unstructured":"Klimontov, V. V., Korbut, A. I., Orlov, N. B., Dashkin, M. V. & Konenkov, V. I. Multiplex bead array assay of a panel of circulating cytokines and growth factors in patients with albuminuric and non-albuminuricdiabetic kidney disease. J. Clin. Med. 9, 3006 (2020).","journal-title":"J. Clin. Med."},{"key":"462_CR105","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/jch.13450","volume":"21","author":"KS Petersen","year":"2019","unstructured":"Petersen, K. S. et al. Paucity of high-quality studies reporting on salt and health outcomes from the science of salt: a regularly updated systematic review of salt and health outcomes (April 2017 to March 2018). J. Clin. Hypertens. 21, 307\u2013323 (2019).","journal-title":"J. Clin. Hypertens."},{"key":"462_CR106","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S2213-8587(14)70156-1","volume":"2","author":"Look AHEAD Research Group.","year":"2014","unstructured":"Look AHEAD Research Group. Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol. 2, 801\u2013809 (2014).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"462_CR107","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.2337\/dc06-1998","volume":"30","author":"H Makino","year":"2007","unstructured":"Makino, H. et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 30, 1577\u20131578 (2007).","journal-title":"Diabetes Care"},{"key":"462_CR108","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1056\/NEJMoa1111732","volume":"365","author":"DCCT\/EDIC Research Group","year":"2011","unstructured":"DCCT\/EDIC Research Group. et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N. Engl. J. Med. 365, 2366\u20132376 (2011).","journal-title":"N. Engl. J. Med."},{"key":"462_CR109","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/ki.2012.401","volume":"83","author":"V Perkovic","year":"2013","unstructured":"Perkovic, V. et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int. 83, 517\u2013523 (2013).","journal-title":"Kidney Int."},{"key":"462_CR110","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1053\/j.ajkd.2009.03.022","volume":"54","author":"HM Colhoun","year":"2009","unstructured":"Colhoun, H. M. et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am. J. Kidney Dis. 54, 810\u2013819 (2009).","journal-title":"Am. J. Kidney Dis."},{"key":"462_CR111","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1053\/j.ajkd.2004.11.004","volume":"45","author":"JC Ansquer","year":"2005","unstructured":"Ansquer, J. C. et al. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am. J. Kidney Dis. 45, 485\u2013493 (2005).","journal-title":"Am. J. Kidney Dis."},{"key":"462_CR112","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s00125-010-1951-1","volume":"54","author":"TM Davis","year":"2011","unstructured":"Davis, T. M. et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia 54, 280\u2013290 (2011).","journal-title":"Diabetologia"},{"key":"462_CR113","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","volume":"362","author":"ACCORD Study Group","year":"2010","unstructured":"ACCORD Study Group. et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med. 362, 1563\u20131574 (2010).","journal-title":"N. Engl. J. Med."},{"key":"462_CR114","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10157-020-01959-9","volume":"25","author":"T Wada","year":"2021","unstructured":"Wada, T. et al. Effects of LDL apheresis on proteinuria in patients with diabetes mellitus, severe proteinuria, and dyslipidemia. Clin. Exp. Nephrol. 25, 1\u20138 (2021).","journal-title":"Clin. Exp. Nephrol."},{"key":"462_CR115","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","volume":"7","author":"BL Neuen","year":"2019","unstructured":"Neuen, B. L. et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 7, 845\u2013854 (2019).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"462_CR116","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1681\/ASN.2019111168","volume":"31","author":"MJ Jardine","year":"2020","unstructured":"Jardine, M. J. et al. Renal, cardiovascular, and safety outcomes of canagliflozin by baseline kidney function: a secondary analysis of the CREDENCE randomized trial. J. Am. Soc. Nephrol. 31, 1128\u20131139 (2020).","journal-title":"J. Am. Soc. Nephrol."},{"key":"462_CR117","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.coph.2020.08.018","volume":"54","author":"M Vitale","year":"2020","unstructured":"Vitale, M., Haxhi, J., Cirrito, T. & Pugliese, G. Renal protection with glucagon-like peptide-1 receptor agonists. Curr. Opin. Pharmacol. 54, 91\u2013101 (2020).","journal-title":"Curr. Opin. Pharmacol."},{"key":"462_CR118","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41581-020-00367-2","volume":"17","author":"RZ Alicic","year":"2021","unstructured":"Alicic, R. Z., Cox, E. J., Neumiller, J. J. & Tuttle, K. R. Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence. Nat. Rev. Nephrol. 17, 227\u2013244 (2021).","journal-title":"Nat. Rev. Nephrol."},{"key":"462_CR119","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1111\/dom.14281","volume":"23","author":"DV O\u2019Hara","year":"2020","unstructured":"O\u2019Hara, D. V. et al. The effects of dipeptidyl peptidase-4 inhibitors on kidney outcomes. Diabetes Obes. Metab. 23, 763\u2013773 (2020).","journal-title":"Diabetes Obes. Metab."},{"key":"462_CR120","first-page":"CD007004","volume":"10","author":"EY Chung","year":"2020","unstructured":"Chung, E. Y. et al. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst. Rev. 10, CD007004 (2020).","journal-title":"Cochrane Database Syst. Rev."},{"key":"462_CR121","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris, G. L. et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N. Engl. J. Med. 383, 2219\u20132229 (2020).","journal-title":"N. Engl. J. Med."},{"key":"462_CR122","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1681\/ASN.2019060582","volume":"31","author":"M Sugahara","year":"2020","unstructured":"Sugahara, M. et al. Prolyl hydroxylase domain inhibitor protects against metabolic disorders and associated kidney disease in obese type 2 diabetic mice. J. Am. Soc. Nephrol. 31, 560\u2013577 (2020).","journal-title":"J. Am. Soc. Nephrol."},{"key":"462_CR123","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ki.2010.483","volume":"80","author":"AS Levey","year":"2011","unstructured":"Levey, A. S. et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 80, 17\u201328 (2011).","journal-title":"Kidney Int."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41581-021-00462-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-021-00462-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-021-00462-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T10:26:10Z","timestamp":1634207170000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41581-021-00462-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,6]]},"references-count":123,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["462"],"URL":"https:\/\/doi.org\/10.1038\/s41581-021-00462-y","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,6]]},"assertion":[{"value":"23 June 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}